Levodopa/Benserazide PLGA Microsphere Prevents L-Dopa Induced Dyskinesia via Lower beta-Arrestin2 in 6-Hydroxydopamine Parkinson's Rats

doi:10.3389/fphar.2019.00660

科研成果详情

题名	Levodopa/Benserazide PLGA Microsphere Prevents L-Dopa Induced Dyskinesia via Lower beta-Arrestin2 in 6-Hydroxydopamine Parkinson's Rats
作者	Wang, Wen-Wen1; Zhang, Xing-Ru 2; Lin, Jing-Ya 3; Zhang, Zeng-Rui 2; Wang, Zhen2; Chen, Si-Yan2; Xie, Cheng-Long 2
发表日期	2019-06-14
发表期刊	FRONTIERS IN PHARMACOLOGY 影响因子和分区
语种	英语
原始文献类型	Article
关键词	beta-arrestin2 Levodopa/benserazide PLGA microsphere Parkinson's disease L-dopa-induced dyskinesia LBPM
其他关键词	LEVODOPA-INDUCED DYSKINESIA ; QUALITY-OF-LIFE ; METHYL ESTER/BENSERAZIDE ; DISEASE ; RECEPTOR ; EXPRESSION ; ROPINIROLE ; INFUSION
摘要	Prolonged pulsatile administration of Levodopa (L-dopa) can generate L-dopa-induced dyskinesia (LID). Numerous research has reported that continuous dopamine delivery (CDD) was useful in reducing the severity of LID. 6-OHDA lesioned rats were divided into two groups to receive intermittent L-dopa stimulation (L-dopa/benserazide) or Levodopa/benserazide PLGA microsphere (LBPM) for 3 weeks. rAAV (recombinant adeno-associated virus) vector was used to overexpress and ablation of beta-arrestin2. We found that LBPM developed less AIM severity compared with standard L-dopa administration, whereas selective deletion of beta-arrestin2 in striatum neurons dramatically enhanced the severity of dyskinesia by LBPM. On the contrary, the effects of LBPM in terms of ALO AIM were further relieved by beta-arrestin2 overexpression. Furthermore, no significant change in motor behavior was seen either in inhibition or overexpression of beta-arrestin2. In short, our experiments provided evidence that LBPM's prevention of LID behavior was likely due to beta-arrestin2, suggesting that a therapy modulating beta-arrestin2 may offer a more efficient anti-dyskinetic method with a low risk of untoward effects.
资助项目	National Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81600977]; Wenzhou City Committee of Science and Technology [Y20180137, Y20170067]; Natural Science Foundation of Zhejiang ProvinceNatural Science Foundation of Zhejiang Province [Y19H090059]
出版者	FRONTIERS MEDIA SA
出版地	LAUSANNE
ISSN	1663-9812
卷号	10 期号:JUN 页码:660
DOI	10.3389/fphar.2019.00660
页数	11
WOS类目	Pharmacology & Pharmacy
WOS研究方向	Pharmacology & Pharmacy
WOS记录号	WOS:000471884100001
收录类别	SCIE ; PUBMED ; SCOPUS
URL	查看原文
PubMed ID	31275144
PMC记录号	PMC6593297
SCOPUSEID	2-s2.0-85069790877
通讯作者地址	[Chen, Si-Yan]Department of Neurology,First Affiliated Hospital of Wenzhou Medical University,Wenzhou,China
Scopus学科分类	Pharmacology;Pharmacology (medical)
引用统计	被引频次：6[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/17776
专题	第二临床医学院、附属第二医院、育英儿童医院_中医系附属第二医院附属第一医院第一临床医学院（信息与工程学院）、附属第一医院_内科学_神经内科
通讯作者	Chen, Si-Yan
作者单位	1.Center of Traditional Chinese Medicine,Second Affiliated Hospital,Yuying Children’s Hospital of Wenzhou Medical University,Wenzhou,China; 2.Department of Neurology,First Affiliated Hospital of Wenzhou Medical University,Wenzhou,China; 3.Department of Neurology,Xinhua Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai,China
第一作者单位	附属第二医院
通讯作者单位	附属第一医院
第一作者的第一单位	附属第二医院
推荐引用方式 GB/T 7714	Wang, Wen-Wen,Zhang, Xing-Ru,Lin, Jing-Ya,et al. Levodopa/Benserazide PLGA Microsphere Prevents L-Dopa Induced Dyskinesia via Lower beta-Arrestin2 in 6-Hydroxydopamine Parkinson's Rats[J]. FRONTIERS IN PHARMACOLOGY,2019,10(JUN):660.
APA	Wang, Wen-Wen., Zhang, Xing-Ru., Lin, Jing-Ya., Zhang, Zeng-Rui., Wang, Zhen., ... & Xie, Cheng-Long. (2019). Levodopa/Benserazide PLGA Microsphere Prevents L-Dopa Induced Dyskinesia via Lower beta-Arrestin2 in 6-Hydroxydopamine Parkinson's Rats. FRONTIERS IN PHARMACOLOGY, 10(JUN), 660.
MLA	Wang, Wen-Wen,et al."Levodopa/Benserazide PLGA Microsphere Prevents L-Dopa Induced Dyskinesia via Lower beta-Arrestin2 in 6-Hydroxydopamine Parkinson's Rats".FRONTIERS IN PHARMACOLOGY 10.JUN(2019):660.